WAT · Waters Corp /De/
One customer — 10% of receivables (the three months ended April 4, 2026)
“The Company considers this to be a significant concentration of credit risk, as it accounts for greater than 10% of the Company’s accounts receivables for the three months ended April 4, 2026.”
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $3.05 | Q2 2026 | — |
| Advanced Diagnostics Division (ADx) Clinical Business Unit reported revenue | 72M | Q2 2026 | — |
| Advanced Diagnostics Division (ADx) Diagnostic Solutions reported revenue | 449M | Q2 2026 | — |
| Analytical Sciences Division (ASD) reported revenue | 669M | Q2 2026 | — |
| Biosciences and Diagnostic Solutions revenue | 817M | Q2 2026 | — |
| Biosciences Division (WBD) reported revenue | 368M | Q2 2026 | — |
| Materials Sciences Division (MSD) reported revenue | 87M | Q2 2026 | — |
| Organic constant currency revenue growth non-GAAP | 9% | Q2 2026 | — |
| Organic revenue non-GAAP | 828M | Q2 2026 | — |
| Constant currency growth rate non-GAAP | 8% | Twelve Months Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WAT
this stock
Waters Corp /De/
|
$40.49B | +8.5% | +7.0% | — | 4.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$141.79B | -11.6% | +8.5% | 35.8 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.02B | -18.6% | +10.4% | 38.4 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WAT | +1.3% | +11.7% | +25.8% | +9.2% | +8.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.9% | +7.3% | +12.0% | +5.3% | -5.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.